MRD in Multiple Myeloma: “The Utility Is Undeniable,” Although Use in Clinical Decision Making is Premature

10.26.20

MRD in Multiple Myeloma: “The Utility Is Undeniable,” Although Use in Clinical Decision Making is Premature

by Eleanor Mayfield, ELS

Survey: Clinicians Are Assessing MRD in Multiple Myeloma, but Demur at Using It to Make Treatment Decisions

09.30.20

Survey: Clinicians Are Assessing MRD in Multiple Myeloma, but Demur at Using It to Make Treatment Decisions

by Eleanor Mayfield, ELS

“Impressive” Results for Investigational BiTEs Seen in Phase 1 Myeloma Studies

09.18.20

“Impressive” Results for Investigational BiTEs Seen in Phase 1 Myeloma Studies

by Eleanor Mayfield, ELS

Incyte Announces Recipient of Incyte Ingenuity Award

09.18.20

Incyte Announces Recipient of Incyte Ingenuity Award

by Kate Jacobson

STING Protein Pathway Can Protect Certain Patients from GVHD, Study Finds

09.10.20

STING Protein Pathway Can Protect Certain Patients from GVHD, Study Finds

by Kate Jacobson

New Study Finds T-Cells Play Unappreciated Role in Acute GVHD

08.30.20

New Study Finds T-Cells Play Unappreciated Role in Acute GVHD

by Kate Jacobson

Best Practices in MRD Quantification: The Importance of the First Bone Marrow Pull

08.28.20

Best Practices in MRD Quantification: The Importance of the First Bone Marrow Pull

by Eleanor Mayfield, ELS

Emergence of Non-Steroid Treatments is One of Most “Exciting Developments” in GVHD, Doctor Says

08.21.20

Emergence of Non-Steroid Treatments is One of Most “Exciting Developments” in GVHD, Doctor Says

by Kate Jacobson

“Acceptable” Results in AMG 330 Phase I Dose-Escalation Study

08.03.20

“Acceptable” Results in AMG 330 Phase I Dose-Escalation Study

by Eleanor Mayfield, ELS

Theme picker

Thank you to our sponsors